2014年4月16日星期三

Nilotinib |cas 641571-10-0 |DC Chemicals|Supplier|Price|Buy

DC Chemicals Supply: Nilotinib ,cas 641571-10-0, Cat No. DC3144, In stock

Contact: website: www.dcchemicals.com,
sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,
Tel: +86-21-61454686;Fax:+86-21-61642650;

Product name: Nilotinib, Synonym: Tasigna, Cat No. DC3144, Cas: 641571-10-0, Chemical Name:4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide, Molecular Formula: C28H22F3N7O, MW: 529.52

Nilotinib Cas#641571-10-0.Purity:>98%.Best Price and Quality in the Market!Supplied by DC Chemicals! Nilotinib (AMN-107, Tasigna) is a Bcr-Abl inhibitor with IC50 less than 30 nM.

Nilotinib is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) 
For the detailed information about the solubility of Nilotinib in water, the solubility of Nilotinib in DMSO, the solubility of Nilotinib in PBS buffer, the animal experiment of Nilotinib,the in vivo and in vitro test of Nilotinib,the cell experiment of Nilotinib,the IC50 and EC50 of Nilotinibplease contact DC Chemicals.

没有评论:

发表评论